Patents by Inventor Fletcher B. Taylor, Jr.

Fletcher B. Taylor, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6838432
    Abstract: A method for inhibiting and for reversing the dysfunctional response of vascular endothelial cells to an inflammatory stimulus in a subject in need of such therapy has been developed in which an effective amount of a pharmaceutical composition comprising thrombin-activatable fibrinolysis inhibitor (TAFI) combined with a pharmaceutically acceptable carrier and optionally other treatments is administered to the subject.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: January 4, 2005
    Assignees: Oklahoma Medical Research Foundation, McMaster University
    Inventors: Fletcher B. Taylor, Jr., Laszlo Bajzar
  • Patent number: 5120537
    Abstract: An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a preferred embodiment, Factor Xa, a serine esterase that forms a complex with Factor Va, Ca++, and phospholipid to catalyze prothrombin activation, is first inactivated with an active site inhibitor, such as dansyl-glu- gly-arg-chloromethyl ketone, to form inactivated factor Xa. In another embodiment, Factor Xa is expressed from a gene sequence wherein the portion encoding the active serine region is modified. The inactivated protein retains the ability to bind to endogenous factor Va in vivo, and has a half-life of approximately ten hours. Administration of inactive factor Xa to the blood of a patient results in the formation of inactive factor Xa-Va complexes in vivo, thereby inhibiting coagulation.
    Type: Grant
    Filed: June 14, 1989
    Date of Patent: June 9, 1992
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Charles T. Esmon, Fletcher B. Taylor, Jr.
  • Patent number: 5009889
    Abstract: A pharmaceutical composition comprising activated protein C activity is used to treat subjects for permeability and coagulopathic dysfunctions of vascular endothelial cells in response to an inflammatory stimulus. The composition may be used to prevent or to reverse these pathological events. Further, the composition is used to prevent elevated plasma levels of tumor necrosis factor, an inflammatory mediator which participates in the chain of events which produce the dysfunctional responses.
    Type: Grant
    Filed: December 31, 1987
    Date of Patent: April 23, 1991
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Fletcher B. Taylor, Jr., Charles T. Esmon